Patents Assigned to VASCULEAD INC.
  • Partner of SLD five 1 (PSF1)-derived peptide
    Patent number: 10617750
    Abstract: A Partner of Sld Five 1 (PSF1)-derived peptide that can induce a Cytotoxic T-Cell (CTL) response useful for a specific immunotherapy for cancer patients and a pharmaceutical composition for treating or preventing cancer, which contains the peptide according to the present invention are described.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: April 14, 2020
    Assignee: Vasculead Inc.
    Inventors: Hidekazu Tanaka, Motofumi Iguchi, Mari Yokoyama
  • PARTNER OF SLD FIVE 1 (PSF1)-DERIVED PEPTIDE
    Publication number: 20180169203
    Abstract: A Partner of Sld Five 1 (PSF1)-derived peptide that can induce a Cytotoxic T-Cell (CTL) response useful for a specific immunotherapy for cancer patients and a pharmaceutical composition for treating or preventing cancer, which contains the peptide according to the present invention are described.
    Type: Application
    Filed: February 7, 2018
    Publication date: June 21, 2018
    Applicant: Vasculead Inc.
    Inventors: Hidekazu TANAKA, Motofumi IGUCHI, Mari YOKOYAMA
  • Partner of SLD five 1 (PSF1)-derived peptide
    Patent number: 9919039
    Abstract: A Partner of Sld Five 1 (PSF1)-derived peptide that can induce a Cytotoxic T-Cell (CTL) response useful for a specific immunotherapy for cancer patients and a pharmaceutical composition for treating or preventing cancer, which contains the peptide according to the present invention are described.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: March 20, 2018
    Assignee: VASCULEAD INC.
    Inventors: Hidekazu Tanaka, Motofumi Iguchi, Mari Yokoyama